title: Rituximab followed by mycophenolate mofetil in children with IgM nephropathy.
abstract: IgM nephropathy presents with refractory nephrotic syndrome and its treatment is a significant challenge for pediatricians. We present two patients with IgM nephropathy and frequently relapsing nephrotic syndrome treated with rituximab and subsequently mycophenolate mofetil. Both showed complete remission, which 24 to 30 months later, was still maintained. The role of mycophenolate mofetil therapy in maintaining remission after successful treatment of rituximab in IgM nephropathy needs to be examined.
authors.affiliation: Department of Nephrology, The Childrens Hospital of Zhejiang University School of Medicine, Hangzhou 310003, China.
authors.forename: Jin'ai
authors.initials: J
authors.lastname: Gu
authors.forename: Yonghui
authors.initials: Y
authors.lastname: Xia
authors.forename: Jianhua
authors.initials: J
authors.lastname: Mao
authors.forename: Haidong
authors.initials: H
authors.lastname: Fu
authors.forename: Ai'min
authors.initials: A
authors.lastname: Liu
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007075:Immunoglobulin M; D007155:Immunologic Factors / Q000627:therapeutic use*; D007223:Infant; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009404:Nephrotic Syndrome / Q000188:drug therapy*; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007075:Immunoglobulin M; D007155:Immunologic Factors; D000069283:Rituximab; D009173:Mycophenolic Acid